|
Real-time
Euronext Paris
10:21:55 2026-08-12 EDT
|
5-day change | 1st Jan Change | ||
| 13.24 EUR | +2.16% |
|
-5.97% | +151.47% |
| 07-03 | Genfit soars on news of U.S. reimbursement for a product |  |
| 07-03 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
Company Valuation: GENFIT
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 214.6 | 197 | 176 | 176.3 | 262.2 | 648.3 | - | - |
| Change | - | -8.19% | -10.69% | 0.17% | 48.73% | 147.29% | - | - |
| Enterprise Value (EV) 1 | 30.1 | 131.8 | 168.4 | 156.6 | 166.7 | 597.2 | 582.1 | 615.1 |
| Change | - | 337.75% | 27.79% | -6.98% | 6.41% | 258.35% | -2.52% | 5.66% |
| P/E | 3.51x | -8.27x | -6.1x | 118x | -3.06x | 33.4x | 86.1x | 11.8x |
| PBR | 2.55x | - | 2.59x | 2.54x | - | 8.24x | 9.9x | -52.8x |
| PEG | - | 0x | -0.3x | -1x | 0x | -0x | -1.4x | 0x |
| Capitalization / Revenue | 2.51x | 7.42x | 4.61x | 2.48x | 3.69x | 6.47x | 5.23x | 4.4x |
| EV / Revenue | 0.35x | 4.96x | 4.41x | 2.21x | 2.34x | 5.96x | 4.69x | 4.17x |
| EV / EBITDA | 0.87x | -5.18x | -6.75x | 31.3x | -3.22x | 21.3x | 9.6x | 8.53x |
| EV / EBIT | 0.95x | -4.83x | -6.33x | 47.7x | -37x | 17.5x | 8.69x | 7.24x |
| EV / FCF | 0.3x | - | -3.02x | 10.7x | -6.04x | 30x | 57.4x | 14.6x |
| FCF Yield | 330% | - | -33.2% | 9.35% | -16.6% | 3.33% | 1.74% | 6.87% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.23 | -0.48 | -0.58 | 0.03 | -1.72 | 0.3876 | 0.1506 | 1.098 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 85.58 | 26.57 | 38.18 | 70.94 | 71.12 | 100.2 | 124 | 147.5 |
| EBITDA 1 | 34.56 | -25.46 | -24.93 | 5.005 | -51.79 | 28.08 | 60.67 | 72.14 |
| EBIT 1 | 31.82 | -27.29 | -26.58 | 3.281 | -4.5 | 34.22 | 66.98 | 84.94 |
| Net income 1 | 67.26 | -23.72 | -28.89 | 1.507 | -85.97 | 22.88 | 6.8 | 33.27 |
| Net Debt 1 | -184.5 | -65.28 | -7.611 | -19.66 | -95.52 | -51.12 | -66.17 | -33.21 |
| Reference price 2 | 4.32 | 3.97 | 3.54 | 3.54 | 5.26 | 12.96 | 12.96 | 12.96 |
| Nbr of stocks (in thousands) | 49,727 | 49,655 | 49,712 | 49,865 | 49,795 | 50,024 | - | - |
| Announcement Date | 4/7/22 | 4/13/23 | 4/4/24 | 4/24/25 | 4/2/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.44x | 5.96x | 21.26x | -.--% | 748M | |
| 33.79x | 6.03x | 17.93x | 0.95% | 49.54B | |
| -21.33x | 304.18x | -21.64x | -.--% | 44.06B | |
| 47.52x | 5.43x | 29.85x | -.--% | 40.85B | |
| 31.4x | 3.1x | 13.37x | -.--% | 40.14B | |
| 32.03x | 9.22x | 23.17x | 0.36% | 34.17B | |
| 34.43x | 5.65x | 25.65x | -.--% | 16.9B | |
| 23.25x | 2.04x | 8.83x | 1.16% | 14B | |
| 75.45x | 3.98x | 15.45x | -.--% | 13.46B | |
| Average | 32.22x | 38.40x | 14.88x | 0.27% | 28.21B | |
| Weighted average by Cap. | 27.49x | 57.29x | 12.86x | 0.3% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GNFT Stock
- Valuation GENFIT
Select your edition
All financial news and data tailored to specific country editions
